The size of the Global Kidney Cancer Diagnostics and Therapeutics Market is forecasted to be growing at a CAGR of 5.64% from 2022 to 2027. The size of the market is predicted to be worth USD 4.82 billion by 2027 from USD 3.67 billion in 2022.
Though there has been considerable development in science and technology to tackle cancer, it continues to threaten lives worldwide. Kidney cancer is one of the frequent urologic tumors accounting for around 3% of all human cancers. The frequency rate of renal cell carcinoma has increased gradually in recent decades.
MARKET DRIVERS:
Y-O-Y growth in the adoption of advanced therapy techniques such as cytokine-based treatment primarily accelerates the growth rate of the global kidney cancer diagnostics and therapeutics market.
The growing economies of the various countries are helping the healthcare industry grow at a high pace, further contributing to the growth of the global kidney cancer diagnostics and therapeutics market. Increasing demand for novel and effective diagnostics and therapeutics is another major factor catalyzing the growth of the Global Kidney Cancer Diagnostics and Therapeutics Market. Also, increased investments from governments and private organizations for research and development to develop minimally invasive techniques and the emergence of effective therapy procedures such as nephrectomy boost the global kidney cancer diagnostics and therapeutics market.
The emergence of novel and innovative diagnostics and therapeutic procedures such as cytokine and nephrectomy boost the growth opportunities for key market players in this market, promoting growth during the forecast period across the world. The increasing prevalence of the geriatric population and growing demand for extensive diagnostics tests leads to the development and adoption of novel therapy procedures, which is creating several growth opportunities for the stakeholders operating in the global kidney cancer diagnostics therapeutics market. An increasing number of research and development activities for kidney cancer diagnostics and the emergence of technically advanced tests are likely to expand growth opportunities for the key players functioning in the international marketplace.
MARKET RESTRAINTS:
High costs associated with branded cancer drugs are the major challenge limiting the growth of the worldwide market. The increasing adoption rate of generic drugs is another major challenge restricting the development of the global kidney cancer diagnostics and therapeutics market.
Impact of COVID-19 on the global kidney cancer diagnostics and therapeutics market:
The SARS-CoV-2 reagent is responsible for the novel coronavirus (COVID 19) that has affected millions of human lives spreading to every corner of the world. The rapid spread of the coronavirus has caused drastic changes over the healthcare systems worldwide, impacting the patients affected with COVID 19. The kidney-related diagnosis and treatment procedures and all other elective surgeries were delayed. In general, patients with chronic renal diseases are at high risk of acute COVID 19 infections. Patients with renal cell carcinoma more vulnerable to infections because of the disorders in the immune system.
Moreover, the COVID vaccination is proven to be effective and safe. The virus continues to impact patient care suffering from renal cell carcinoma and other cancer diseases in multiple ways. Millions of cancer patients are battling against the COVID 19, and if any cancer patient is tested positive, they should make some efforts to delay surgeries until they recover fully. Cancer patients develop a small risk of allergic reaction to the COVID vaccine. Patients undergoing hemodialysis infected with COVID 19 need to continue their regimen and stay at their present center to reduce the risk of infection to other patients and healthcare personnel.
REPORT COVERAGE:
|
REPORT METRIC |
DETAILS |
|
Market Size Available |
2021 to 2027 |
|
Base Year |
2021 |
|
Forecast Period |
2022 to 2027 |
|
Segments Covered |
By Type, Tests, and Region |
|
Various Analyses Covered |
Global, Regional & Country Level Analysis, Segment-Level Analysis, DROC, PESTLE Analysis, Porter’s Five Forces Analysis, Competitive Landscape, Analyst Overview on Investment Opportunities |
|
Regions Covered |
North America, Europe, APAC, Latin America, Middle East & Africa |
|
Market Leaders Profiled |
GlaxoSmithKline, Bayer, Pfizer, Sanofi S.A., Hoffmann La Roche, Novartis, and Abbott Laboratories |
This research report on the global kidney cancer diagnostics and therapeutics market has been segmented and sub-segmented based on the type, tests, and region.
Kidney Cancer Diagnostics and Therapeutics Market – By Type:
The type of Renal Cell Carcinoma (RCC) is expected to account for the highest share in the kidney cancer diagnostics and therapeutics market. It is a type of kidney cancer. The RCC owes to the disease's high frequency, the existence of diagnostic procedures, and treatment therapies. RCC is most commonly seen in children and makes up to 2% to 6% of childhood. RCC affects 70% of the patients, and RCC's occurrence rate is high in North America. Around 270,000 new cases are diagnosed yearly, and out of those, 116,000 deaths took place. Regular renal cell carcinoma has been increasing steadily over the last twenty years. The factors responsible for RCC are lifestyle changes, genomic changes, and advancements in technology. The advanced Renal Cell Carcinoma therapeutics in Japan have achieved steady growth owing to the balance between the approval of combinational therapies and lifestyle changes.
Kidney Cancer Diagnostics and Therapeutics Market – By Tests:
Based on the tests, the biopsy and CT scan segments lead the growth in the market, holding 50% of the share in the market. Recent advancements like biopsy procedures are expected to provide healthy demand for kidney cancer diagnostics. The kidney Ultrasound segment is anticipated to lead the market, followed by biopsy and CT scan. High investments in research and development of kidney cancer diagnostics significantly to enhance the accuracy of early-stage diagnostic tests are boosting the segment growth in the kidney cancer diagnostic and therapeutics market globally.
Kidney Cancer Diagnostics and Therapeutics Market – By Region:
North America accounted for the largest share in the global Kidney Cancer Diagnostics and Therapeutics market, followed by Asia-Pacific and Europe. The frequency of this disease was higher in developed countries than in developing nations due to lifestyle factors. However, the Asia-Pacific region is anticipated to increase at the highest CAGR during the forecast period due to the low expense of drug production and the mounting patient base suffering from these diseases.
KEY MARKET PLAYERS:
Companies dominating the global kidney cancer diagnostics and therapeutics market profiled in this Market are GlaxoSmithKline, Bayer, Pfizer, Sanofi S.A., Hoffmann La Roche, Novartis, and Abbott Laboratories.
1. Introduction
1.1 Market Definition
1.2 Study Deliverables
1.3 Base Currency, Base Year and Forecast Periods
1.4 General Study Assumptions
2. Research Methodology
2.1 Introduction
2.2 Research Phases
2.2.1 Secondary Research
2.2.2 Primary Research
2.2.3 Econometric Modelling
2.2.4 Expert Validation
2.3 Analysis Design
2.4 Study Timeline
3. Overview
3.1 Executive Summary
3.2 Key Inferences
3.3 New Developments
4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)
4.1 Market Drivers
4.2 Market Restraints
4.3 Key Challenges
4.4 Current Opportunities in the Market
5. Market Segmentation
5.1 By Type
5.1.1 Transitional Cell Cancer
5.1.2 Renal cell carcinoma
5.1.3 Renal sarcoma
5.1.4 Other Cancers
5.2 By Tests
5.2.1 Biopsy
5.2.2 CT Scan
5.2.3 Cystoscopy
5.2.4 Intravenous pyelogram
5.2.5 Kidney Ultrasound
6. Geographical Analysis
6.1 North America
6.1.1 Introduction
6.1.2 United States
6.1.3 Canada
6.2 Europe
6.2.1 Introduction
6.2.2 U.K
6.2.3 Spain
6.2.4 Germany
6.2.5 Italy
6.2.6 France
6.3 Asia-Pacific
6.3.1 Introduction
6.3.2 China
6.3.3 India
6.3.4 Japan
6.3.5 South Korea
6.3.6 Australia
6.4 Latin America
6.4.1 Introduction
6.4.2 Brazil
6.4.3 Argentina
6.4.4 Mexico
6.4.5 Rest of Latin America
6.5 Middle East & Africa
6.5.1 Introduction
6.5.2 Middle-East
6.5.3 Africa
7. Pipeline Product Analysis
7.1 Overview
7.2 Pipeline Development Landscape
7.3 Molecular Targets in the Pipeline
7.4 Clinical Trials
7.4.1 Failure Rate by Stage of Development, Indication, Molecule Type and Molecular Target
7.4.2 Clinical Trial Duration by Stage of Development, Indication, Molecule Type and Molecular Target
7.4.3 Clinical Trial Size by Stage of Development, Indication, Molecule Type and Molecular Target.
8.Strategic Analysis
8.1 PESTLE analysis
8.1.1 Political
8.1.2 Economic
8.1.3 Social
8.1.4 Technological
8.1.5 Legal
8.1.6 Environmental
8.2 Porter’s Five analysis
8.2.1 Bargaining Power of Suppliers
8.2.2 Bargaining Power of Consumers
8.2.3 Threat of New Entrants
8.2.4 Threat of Substitute Products and Services
8.2.5 Competitive Rivalry within the Industry
9.Market Leaders' Analysis
9.1 GlaxoSmithKline
9.1.1 Overview
9.1.2 Product Analysis
9.1.3 Strategic Evaluation and Operations
9.1.4 Financial analysis
9.1.5 Legal issues
9.1.6 Recent Developments
9.1.7 SWOT analysis
9.1.8 Analyst View
9.2 Bayer
9.3 Pfizer
9.4 Sanofi S.A
9.5 Hoffmann La Roche
9.6 Novartis
9.7 Abbott Laboratories
10.Competitive Landscape
10.1 Market share analysis
10.2 Merger and Acquisition Analysis
10.3 Agreements, collaborations and Joint Ventures
10.4 New Product Launches
11.Expert Opinions
11.1 Market Outlook
11.2 Investment Opportunities
Appendix
a) List of Tables
b) List of Figures
Related Reports
Talk to our analyst and get customised report done according to your research needs
Check if you can avail any discount. Submit your details and our team will get back to you.
Request to avail a free sample report that reflects this market and its growth.
